2.7-13.8); for radiation maculopathy location of posterior tumour margin within 2 mm from the fovea (HR 3.4, 95% CI 2.0-6.0); and for radiation optic neuropathy location of tumour margin within 1 DD of the optic disc (RR 6.1, 95% CI 3.0-12.4). The 3 and 5 year probabilities of avoiding enucleation were 92% and 85%, respectively. Ten eyes were enucleatedsix because of recurrent tumour growth, three because of treatment complications, and one because of mistakenly suspected extraocular growth.
Abstract
Aimslbackground-To analyse radiation related complications and secondary enucleation after irradiation of malignant uveal melanoma with ruthenium-106 plaques. Methods-A series of 100 consecutive eyes irradiated in 1981-91 was analysed using the life table method and the Cox proportional hazards model. The median apical and scleral tumour dose was 100 Gy (range 15-200 Gy) and 1000 Gy (range 200-1200 Gy), respectively. The median follow up time was 2.8 and 2.0 years (range 1 month to 10 years) for anterior and posterior segment complications, respectively. Results-The 3 and 5 year probabilities of being without radiation cataract were 73% and 63%, without neovascular glaucoma 91% and 81%, without vitreous haemorrhage 83% and 74%, without radiation maculopathy 85% and 70%, and without radiation optic neuropathy 90% The advent of conservative therapies`5 has changed the treatment policy of malignant melanoma of the uvea and has made it possible to preserve the eye and some of the remaining sight for a considerable period of time. However, uveal melanomas are quite resistant to irradiation and the doses needed lead to radiation related complications that become increasingly common during the follow up.-9
Few studies have analysed the occurrence of radiation related complications by correcting statistically for unequal follow up times.'0 11 Such reports are available for uveal melanomas irradiated with charged particles8 12-16 or with cobalt,'7 iodine,'2 8 and ruthenium'9 plaque brachytherapy. They focus on radiation cataract,8 15 7 8 neovascular glaucoma,8 12-14 vitreous haemorrhage,'2 8 radiation maculopathy,'6 and ischaemic radiation optic neuropathy. '9 We report the cumulative probabilities of remaining free from main radiation related complications in a series of 100 eyes of 100 patients treated because of malignant uveal melanoma with ruthenium-106 brachytherapy. We analyse their appearance in relation to the size and location of the tumour,2 4-2022 both known to be risk indicators for loss of vision23 and tumour death.24 Such data on the frequency of complications should prove useful when planning the treatment and counselling the patient. The distance from the posterior tumour margin to the fovea (range 0-17, median 1.5 mm) and to the rim of the optic disc (range 0-14, median 3 mm) were measured by ophthalmoscopy, and confirmed from fundus photographs. They were recordable for all tumours except five located entirely anterior to the equator and for three obscured by hazy media (Table 1) .
During surgery, the tumour was located with the help of trans-scleral illumination with a fibreoptic light, indirect ophthalmoscopy with scleral indentation, or both. The margins of the tumour were marked on the sclera with diathermy. Indentation around the plaque was used to confirm the positioning of very posterior plaques. The median apical and scleral tumour doses were 100 Gy (range 15-200 Gy) and 1000 Gy (range 200-1200 Gy), respectively, delivered within 1 to 23 days (median 5.5 
days).
After irradiation, follow up visits took place 1, 3, 6, and 12 months after irradiation, then twice a year until the fourth postoperative year, and annually thereafter. At every follow up examination a careful clinical evaluation, ultrasonography, and fundus photographs were repeated, while the annual examination additionally included fluorescein angiography.
Follow up data to February 1992 were available for all patients. The median follow up time for development of anterior segment complications was 2.8 years. It was 2.0 years for development of posterior segment complications because of media opacities that increased during the follow up (range for both, 1 month to 10 years). The follow up time was less than 1 year for seven eyes, six of which were enucleated during this time. All except four patients were followed up at our hospital. Their latest follow up data and data from five patients who developed metastases were obtained from other hospitals.
The dates when the various radiation related complications developed were recorded. Generally this had occurred between two follow up examinations, and the eye was censored from analysis at the midpoint of that interval. 22 26 For cataract, rubeosis of the iris, and neovascular glaucoma follow up was taken to end at the latest ophthalmic examination, while for posterior segment complications (vitreous haemorrhage, maculopathy, and optic neuropathy) it ended at the last examination when the posterior segment was still assessable. Two eyes treated for local relapse with an iodine plaque24 were censored on the day preceding the retreatment. Eight eyes irradiated twice with ruthenium were not censored from the analysis. Owing to the low number of these eyes, the influence of repeated brachytherapy could not be analysed separately. The date and the cause of enucleation were recorded.
DEFINITIONS OF RADIATION RELATED COMPLICATIONS
The appearance of either posterior cortical or subcapsular cataract or a sectoral lens opacity1 2 27 that developed or clearly progressed asymmetrically after treatment was interpreted as radiation cataract. It was assessable in 99 eyes; the remaining eye was pseudophakic. Iris rubeosis was defined as new blood vessels over the iris stroma, the chamber angle, or both; and neovascular glaucoma as a rise in intraocular pressure above 23 mm Hg in an eye with iris neovascularisation and a previously normal pressure. They could be assessed in all eyes.
The occurrence of postoperative vitreous haemorrhage could be assessed in 96 eyes; three eyes with a dense haemorrhage present before therapy, and one with a mature cataract at the first postoperative examination were non-assessable. Radiation maculopathy28 was defined as retinal vascular changes such as microaneurysms, haemorrhages, microinfarcts, and lipid exudates seen clinically in the macular area (diameter 1.5 DD). It could be assessed in 85 eyes; in addition to the four eyes mentioned, three were excluded owing to the presence of microaneurysms before therapy, six because of exudative retinal detachment involving the macula, and two because of a 26 Univariate analysis in terms of size and location of the tumour relative to the equator, to the fovea, and to the rim of the optic nerve head was done by the Mantel-Cox test.'0 The size of the tumour was analysed both according to the TNM class25 and the height and LBD of the tumour. Small and medium sized tumours (T1+T2) were combined and compared with large ones (T3). Cutoff points for height and LBD were 5 mm and 15 mm, respectively. Eyes with a tumour at least in part anterior to the equator with or without ciliary body involvement were compared with those in which it was entirely posterior to the equator.
The effect of tumour size was assessed for all complications, the location relative to the equator for all anterior segment complications and vitreous haemorrhage, and the proximity of the posterior tumour margin to the fovea and the optic disc for radiation maculopathy and optic neuropathy, provided that the tumour was located at least in part posterior to the equator. A p value less than 0.05 was considered significant. Cox Fig 1D) , and when the tumour was located at least in part anterior to the equator rather than entirely posterior to it (p=0.0003, Fig 1E) . In Cox proportional hazards multivariate analysis, height of the tumour greater than 5 mm was the strongest predictor of developing a radiation cataract (RR 1.5, 95 % CI 1.4-1.6; p<0.0001, Table 2 ).
Iris rubeosis Neovascularisation of the iris was detected in 12 of 100 eyes (12%) 0.5 to 5.2 years (median 2.4) after irradiation. The overall cumulative 2, 3, and 5 year probabilities of an eye remaining free from iris rubeosis were 95%, 88%, and 80%, respectively (Fig 2A) . Both large tumour size as defined by the TNM class (T1+T2 v T3; p=0.066, Mantel-Cox, Fig 2B) and LBD ( 15mm v >15 mm; p=0.021, Fig 2C) , and location of the tumour at least partially anterior to the equator (p=0.054, Fig 2D) increased the probability of iris rubeosis, but only LBD reached statistical significance. (median 2.6) after the irradiation. In six POSTERIOR SEGMENT COMPLICATIONS ese 10 eyes, exudative retinal detachment Vitreous haemorrhage sted at the latest examination. The cumu-New vitreous haemorrhage occurred in 14 of 2, 3, and 5 year probabilities of an eye 96 eyes (15 %) (including two of four eyes with lining free from neovascular glaucoma bleeding already before therapy) 1.0 week to 96%, 91%, and 81%, respectively (Fig 4.1 years (median 1.4) after irradiation. The Large tumour size as defined by the TNM overall cumulative 2, 3, and 5 year probabilities (T1 +T2 v T3; p=0.039, Mantel-Cox, Fig of an eye remaining free from vitreous haemorand LBD ( 15 mm v >15 mm; p=0.021, rhage were 91%, 83%, and 74%, respectively 3C) was associated with a significantly (Fig 4A) . Bleeding tended to occur more often ased probability of glaucoma, whereas the in eyes with a large tumour as defined by the :ion of the tumour relative to the equator TNM class (Fig 4B), height (Fig 4C) and not statistically significant (Fig 3D) (Fig 5A) . The development of maculopathy was affected by the proximity of the posterior tumour margin to the fovea. A distance of more than 1.5 mm (1 DD) significantly reduced the risk of radiation maculopathy (p=0.030, Mantel-Cox, Fig 5B) . The 2 and 3 year probabilities of an eye being free from maculopathy were 74% and 53% when the tumour was within 1 DD of the fovea compared with 94% and 83% when it was located further than 1 DD, respectively. In Cox multivariate analysis, location of the posterior tumour margin within 2 mm (1.5 DD) from the fovea increased the risk of maculopathy by a factor of 3.4 (95% CI 2.0-6.0, p=0.015, Months Figure 4 Cumulative probabilities (SE) of remainingfree from vitreous haemorrhage after ruthenium-106 brachytherapy for malignant uveal melanoma for all 94 eyes included in the analysis (A). Large size of the tumour as defined by (B) its TNM class (Ti and T2 v T3) and (C) its height (.5 mm v >5 mm) were associated with a tendency to a higher risk ofvitreous haemorrhage. patients, and suspected extrascleral tumour growth not proved by histopathological examination in one patient. The cumulative 2, 3, and 5 year probabilities of escaping enucleation were 92%, 92%, and 85%, respectively (Fig 7A) . Eyes with a large tumour were enucleated significantly more often than those with a small to medium sized tumour (T1+T2 v T3; p=0.0083, MantelCox, Fig 7B) , the 2 and 3 year probabilities being 2% for small to medium sized and 13% for large tumours, respectively. The location of the tumour in relation to the optic disc or fovea was not statistically associated with risk of enucleation.
Discussion
In principle, our results might be compared with the nine previous series of malignant uveal melanoma in which unequal follow up times have been statistically corrected for. 8 12-19 In practice, it is important to take into account differences in study populations, inclusion cri- 17 18 varying from 53% to 66%, whereas that of eyes with a tumour at least in part anterior to the equator varied from 32% to 62% (Table 3) . Three particular series included only tumours that were small to medium sized,14 involved the ciliary body," or were juxtapapillary. '9 In our series, cataract was the most frequent radiation related complication, the cumulative 2, 3, and 5 year probabilities being 21%, 27%, and 37%, respectively. In line with previous data,5 ' Radiation maculopathy competed with cataract as the leading radiation related complication in our series, with cumulative 2 and 3 year probabilities of 15% and 30%, respectively. Optic neuropathy, on the other hand, was relatively uncommon with corresponding frequencies of 10% and 12%, respectively. Their frequencies were expectedly high, since 48% and 23% of the tumours were located within 1 DD of the fovea and the rim of the optic disc, respectively. In such eyes, these complications are common.6 7 20 22 A distance greater than 1.5 mm (1 DD) from the fovea in univariate analysis and more than 2 mm (1.5 DD) in multivariate analysis predicted a significantly reduced risk of radiation maculopathy. This complication was a frequent cause of losing reading vision in the irradiated eye,2" whereas rubeotic glaucoma and enucleation caused loss of light perception.2' The treated eye of 10 patients was enucleated. In six of them this was due to tumour regrowth that usually occurred during the first postoperative year. The 3 and 5 year probabilities of enucleation were 8% and 12%, respectively, similar to other irradiated eyes.8 [12] [13] [14] The goal of irradiation is to destroy all viable tumour and prevent local and systemic relapse. In the present series, the 3 year probabilities of being without local and systemic relapse were 89% and 92%, respectively for small to medium sized melanomas compared with 61 % and 79%, respectively, for large ones.24 A low probability of radiation related complications is an additional benefit to the patient. In our opinion, their frequency in the present series is not unduly high. One third of irradiated eyes in the presently reported group of patients had the same or better visual acuity 1 to 2 years after therapy, and one fifth after 3 years.2' Ruthenium plaques are a viable alternative to arrest tumour growth, save the eye, and retain a considerable proportion of remaining sight, especially when the tumour is small to medium sized.
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